Trial Profile

Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INeo Vac P01 (Primary) ; Granulocyte macrophage colony stimulating factor
Indications Adenocarcinoma; Adrenal cancer; Advanced breast cancer; Biliary cancer; Carcinoma; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
15 Nov 2021 Planned End Date changed from 1 Mar 2021 to 30 Dec 2022.
12 May 2020 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com